Mayara Lee
Cholangiocarcinoma, a challenging malignancy arising from the bile duct epithelium, poses significant diagnostic hurdles due to its asymptomatic nature in early stages and limited effective detection methods. Molecular diagnostics offer a promising avenue for improving early detection and personalized treatment strategies. This abstract explores the concept and potential of an enzymatic fuel-powered dual-wheel molecular device designed for detecting cholangiocarcinoma biomarkers. The device integrates principles from nanotechnology and enzymology, featuring dual wheels driven by enzymatic reactions fueled by specific biochemical substrates. These nanoscale components respond to disease-specific biomolecular interactions associated with cholangiocarcinoma, exhibiting mechanical motion or conformational changes that are detectable through sensitive readout technologies. Such capabilities could enable early detection, facilitate personalized treatment decisions, and provide insights into disease progression monitoring. Key challenges include ensuring biocompatibility, stability in physiological environments, and scalability for clinical application. Addressing these challenges could pave the way for transformative advancements in cholangiocarcinoma diagnostics, offering enhanced sensitivity, specificity, and real-time monitoring capabilities. As research progresses, the enzymatic fuel-powered dual-wheel molecular device holds promise for revolutionizing the landscape of molecular diagnostics, ushering in new opportunities for precision medicine and improved patient outcomes.